VA Bets On MDMA — What’s The Real Play?

The Veterans Affairs Department has opened its first randomized MDMA trial for veterans with post-traumatic stress disorder and alcohol use disorder, and the study could shape how the government treats psychedelic medicine next.

Quick Take

The Department of Veterans Affairs says the study will enroll about 80 veterans and use identical psychotherapy with an active placebo.
The trial is registered on ClinicalTrials.gov as NCT07118839 and is being run at two sites in Rhode Island and Connecticut.
The Veterans Affairs Department says it will use pharmaceutical-grade drugs in a controlled setting and share data with the Food and Drug Administration.
The move follows President Trump’s executive order on accelerating medical treatments for serious mental illness, while veterans groups have publicly backed the trial.

What the new trial is testing

The Veterans Affairs Department has launched a study titled “A Randomized Controlled Trial of MDMA-Assisted Therapy for PTSD and Alcohol Use Disorder in U.S. Veterans.” The agency says it will compare MDMA-assisted therapy with the same psychotherapy paired with an active placebo. The trial is set to recruit about 80 veterans from the Providence, Rhode Island, campus and the Veterans Affairs Connecticut Healthcare System in West Haven.

The design matters because it is meant to test whether the drug adds real benefit beyond therapy alone. The trial is also registered on ClinicalTrials.gov under NCT07118839, which gives the project a public scientific record. A trial registration does not prove success, but it does show the study is structured like formal research rather than an informal pilot program.

Why the Veterans Affairs Department says it is different

The Veterans Affairs Department says the medicines will be used in a safe, controlled clinical setting with pharmaceutical-grade drugs and quality controls developed with the Food and Drug Administration. Officials also say the department is coordinating with the Food and Drug Administration and plans to share trial data with the agency. That step suggests the government wants the study to matter beyond one hospital network and feed into future drug review decisions.

The study also fits a larger federal push toward psychedelic research. The Veterans Affairs Department linked the trial to President Trump’s executive order on accelerating medical treatments for serious mental illness, which aims to speed research and drug review for psychedelic drugs. The department also says it is involved in 19 other psychedelic clinical trials and has more than $23 million in outside funding supporting that work.

What supporters and critics are likely to focus on

Veterans groups have welcomed the trial as a serious effort to help people who have not fully responded to standard treatment. The Veterans of Foreign Wars and Disabled American Veterans both praised the study and framed it as an important step for veteran mental health. That support reflects a long-running frustration on both the right and the left: many families think Washington talks about veterans more than it solves their problems.

Still, the trial has limits that matter. ClinicalTrials.gov says the study excludes people with recent serious suicide risk and requires prior use of at least one first-line PTSD treatment, so the results may not apply to the sickest veterans or to people who have not already failed standard care. The trial also uses an active placebo, which may help blinding but can still leave questions about whether participants can tell which treatment they got.

What changed: in May 2026 the VA launched its own clinical trial of MDMA-assisted therapy for PTSD and alcohol use disorder — about 80 veterans, run through VA sites in Providence, RI and West Haven, CT.

— Psychedelic Vets (@PsychedelicVets) June 29, 2026

The biggest outside concern is regulatory history. The Food and Drug Administration rejected earlier MDMA approval efforts in 2024 because of study design problems, especially blinding and expectancy bias, so the agency will likely judge the new VA data very closely. That makes this trial more than a medical test. It is also a test of whether federal agencies can move from political promises to evidence that survives review.

What veterans should watch next

Veterans interested in the study should watch three things: whether recruitment stays on track, whether the trial can keep participants blinded, and whether the final data show durable symptom relief. The current design is narrow on purpose. It focuses on veterans with both PTSD and alcohol use disorder, uses two sites, and tests one therapy model under strict controls.

If the study produces strong results, it could help MDMA-assisted therapy move closer to broader acceptance. If it falls short, it could reinforce the Food and Drug Administration’s caution and slow the push for psychedelic treatment in veterans care. Either way, the trial now gives the public a clearer way to judge the debate: not by slogans, but by measured results.